SEQ_NO	1	Date of announcement	2026/06/03	Time of announcement	15:29:55
Subject	Phase 1b/2a Clinical Trial Application Submitted to PMDA for a New OBP-301 Indication				
Date of events	2026/06/03	To which item it meets	paragraph 53		

Statement

1.Date of occurrence of the event:2026/06/03
2.Company name:Medigen Biotechnology Corp.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:
Medigen Biotechnology Corp. and the Japanese publicly traded company Oncolys BioPharma (“Oncolys”, TSE stock code 4588), are jointly developing the oncolytic virus new drug OBP-301 (Telomelysin). Oncolys announced today (June 03, 2026) that it had submitted a Phase 1b/2a clinical trial application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for the oncolytic virus OBP-301 in a new indication—lower rectal cancer and anal cancer (the “Study”).
The Study will be conducted as a pilot trial in patients with lower rectal cancer and anal cancer who are candidates for preoperative chemoradiotherapy. OBP-301 will be administered in combination with standard preoperative chemoradiotherapy to evaluate its efficacy and safety. Efficacy will be assessed by measuring local tumor shrinkage following completion of the combined treatment with chemoradiotherapy and OBP-301.
Lower rectal cancer and anal cancer are diseases that often require surgical resection, which typically involves the creation of a gastrointestinal stoma (artificial anus). Such procedures can have a significant impact on patients' quality of life (QOL). Consistent with the development concept of OBP-301, namely ”treating cancer without surgery,” we have decided to expand the development of OBP-301 into the treatment of lower rectal cancer and anal cancer.
6.Countermeasures:none
7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
(1) The development timeline for new drugs is long, requires substantial investment, and does not guarantee success. These factors may pose risks to investors, who are advised to exercise prudent judgment before making investment decisions.
(2) Our company and Oncolys in Japan jointly share the development costs of OBP-301 and will share the future commercial benefits.
(3) Link to the announcement by Oncolys,Japan:
https://ssl4.eir-parts.net/doc/4588/tdnet/2830403/00.pdf